Umeclidinium bromide

Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[2][3] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[4]

Umeclidinium bromide
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration
    Inhalation (DPI)
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Protein binding~89%[1]
    MetabolismHepatic (CYP2D6)
    Elimination half-life11 hours
    ExcretionFeces (58%) and urine (22%)
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEBI
    CompTox Dashboard (EPA)
    ECHA InfoCard100.166.375
    Chemical and physical data
    FormulaC29H34BrNO2
    Molar mass508.500 g·mol−1
    3D model (JSmol)

    References

    1. "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
    2. Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
    3. "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
    4. "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Retrieved 11 July 2020.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.